Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04633330
Recruitment Status : Recruiting
First Posted : November 18, 2020
Last Update Posted : April 12, 2021
Sponsor:
Collaborator:
Qilu Hospital of Shandong University
Information provided by (Responsible Party):
Beihua Kong, Shandong University

Brief Summary:
This is a multi-centre, randomised, double blind, placebo-controlled study on female participants with diagnosis of high-risk human papillomavirus (HR-HPV) infection to evaluate the clearance capacity of AHCC®.

Condition or disease Intervention/treatment Phase
High Risk Human Papillomavirus Infection Low Grade Squamous Intraepithelial Lesion Drug: AHCC®capsules Drug: Simulation of AHCC®capsules Not Applicable

Detailed Description:

Worldwide, cervical cancer is the fourth most common malignancy in women and a major cause of morbidity and mortality. It accounts for nearly 10% of all cancers. The etiology of cervical cancer has been identified and confirmed associated with high risk-human papillomavirus (HR-HPV). When HR-HPV infections persist overtime, patients have an increased risk of developing cervical cancer The proprietary, a standardized extract of cultured Lentinula edodes mycelia (ECLM), AHCC®, was developed in Japan in 1992. Several studies have reported a variety of therapeutic effects, including antioxidant and anticancer activity and improvement of immune response.

As recently reported study on AHCC®, pre-clinical in vitro and in vivo evidence demonstrated its durable clearance of HR-HPV infections. The preliminary data from the two pilot studies suggested that AHCC® supplementation supports the host immune system for successful clearance of HR-HPV infections. A confirmatory phase II randomized, double-blinded, placebo-controlled study is about completion. The preliminary results of this phase II study confirmed data observed in pilot studies that AHCC® supplementation for at least 6 months is associated with a 60% successful elimination of HPV infections and confirmed IFN-β correlates with clearance of persistent HPV infections. The optimal duration of AHCC® supplementation required after the first negative result still needs more evaluation in future clinical studies.

Nevertheless, all above mentioned studies have included western participants solely. The aim of this study is to evaluate the clearance capacity of AHCC® on Chinese female participants with diagnosis of HR-HPV infection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy of AHCC®for the Clearance of High Risk-HPV Infections in Chinese Female: A Multi-centre, Randomised, Double Blind and Placebo-controlled Study
Actual Study Start Date : October 26, 2020
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : August 31, 2023

Arm Intervention/treatment
Experimental: Study Arm
AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
Drug: AHCC®capsules
AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
Other Name: Yinuojin Ruanjiaonang

Placebo Comparator: Control Arm
Simulation of AHCC®capsules, 5 capsules * 3 times per day, empty stomach (defined as one hour before meal or two hours after meal).
Drug: Simulation of AHCC®capsules
TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
Other Name: Yinuojin Ruanjiaonang Moniji




Primary Outcome Measures :
  1. High risk human papillomavirus (HR-HPV) infection testing, ROCHE, Cobas assay [ Time Frame: 6 months for all participants since enrolment ]
    The Cobas human papillomavirus (HPV) test is NMPA-approved for cervical and endocervical samples collected in PreservCyt (ThinPrep) media. The Cobas HPV test detects DNA of the high-risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. This test does not detect DNA of HPV low-risk types (e.g., 6, 11, 42, 43, 44) since these are not associated with cervical cancer and its precursor lesions.


Secondary Outcome Measures :
  1. Interferon Beta Test-Plasma [ Time Frame: 3 months and 6 months for all participants since enrolment, extra-6 month for responding participant from study arm, extra 3 months and 6 months for compensated participants from control arm. ]
    Human IFN-β (Interferon beta) ELISA Kit will be applied for this test. This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Capture antibody was precoated onto 96-well plates. And the biotin conjugated antibody was used as detection antibodies. The standards, test samples and biotin conjugated detection antibody were added to the wells subsequently, and washed with wash buffer. HRP-Streptavidin was added and unbound conjugates were washed away with wash buffer. TMB substrates were used to visualize HRP enzymatic reaction. TMB was catalysed by HRP to produce a blue colour product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the target amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of target can be calculated.


Other Outcome Measures:
  1. Liquid based cytology test [ Time Frame: 6 months for all participants since enrolment, extra-6 month for responding participant from study arm, and extra 6 months for compensated participants from control arm. ]
    In this method, the cervical cells are immersed in a conserving liquid before being fixed on the slide, avoiding desiccation and reducing the quantity of obscuring material. Liquid cytology can be prepared by manual or automated methods, and various systems are commercially available. They are mostly used for cervical cancer screening but are also adapted for FNAC samples.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Sign the informed consent form
  • Not menopausal
  • Met persistent HR-HPV infection criteria:
  • At least one HR-HPV positive test over 12 months prior to screening
  • HR-HPV positive diagnosis by Cobas assay within 3 months prior to screening
  • Low grade squamous intraepithelial lesion (LSIL) diagnosis by cytology within 6 months prior to screening
  • Willing to take effective contraception method during study period.
  • Negative urine pregnancy test within 7 days prior to screening
  • Normal haematology, kidney and liver functions: ANC≥1,500 cells/mm3, platelets 100,000≥cells/mm3, creatinine clearance ≥60mL/min (estimated using Cockcroft Gault equation), total bilirubin, serum alanine aminotransferase (SGPT), serum aspartate aminotransferase (SGOT), and alkaline phosphatase ≤ normal value 1.5 Times.

Exclusion Criteria:

  • With following medical history within 6 months prior to screening: myocardial infarction, unstable angina, heart failure, or un-controlled hypertension (>140/90 mmHg)
  • Systemic treatment for HR-HPV infection has been performed within three months before screening
  • Acute genital tract infection
  • Previously or currently diagnosed as malignant tumour
  • The cytological diagnosis is: ASC-H, AGC tends to become tumorous and other high-risk lesions
  • The histological diagnosis is High grade squamous intraepithelial lesion (HSIL)
  • Pregnant or breastfeeding
  • A history of hepatitis (autoimmune, A, B, or C) or positive antigen
  • There is a clear history of mental confusion (schizophrenia, two-way affection, psychosis) or uncontrolled epilepsy
  • The main gynaecologist believes that there are significant medical complications, including immunosuppressive conditions (such as HIV, Rheumatoid arthritis, etc.) or are taking immunomodulators (such as immunosuppressive agents)
  • Participants with autoimmune diseases
  • Taking AHCC® capsules before screening
  • Taking other immune-modulating nutritional supplements
  • Planned hysterectomy (excluding subtotal hysterectomy)
  • Considered by investigators as unsuitable participant of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04633330


Locations
Layout table for location information
China, Shandong
Qilu Hospital of Shandong University Recruiting
Jinan, Shandong, China, 250012
Contact: Beihua Kong, MD. PhD.    +8618560081888    kongbeihua@sdu.edu.cn   
Sponsors and Collaborators
Shandong University
Qilu Hospital of Shandong University
Layout table for additonal information
Responsible Party: Beihua Kong, Professor, PhD, Shandong University
ClinicalTrials.gov Identifier: NCT04633330    
Other Study ID Numbers: AHCC-WM-0520
First Posted: November 18, 2020    Key Record Dates
Last Update Posted: April 12, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The desensitised protocol and metadata will be publicly available after completion.
Supporting Materials: Study Protocol
Time Frame: The sharing data will be available after Dec. 2021.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Beihua Kong, Shandong University:
HR-HPV
AHCC®
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Papillomavirus Infections
Disease Attributes
Pathologic Processes
DNA Virus Infections
Virus Diseases
Tumor Virus Infections